$12.48
-0.44[-3.41%]
At close: Apr 25
$12.48
0[0.00%]
After Hours: 4:20PM EDT
Enanta Pharma
(NASDAQ:ENTA)Enanta Pharma Stock (NASDAQ:ENTA), Analyst Ratings, Price Targets, Predictions
Enanta Pharmaceuticals Inc has a consensus price target of $51.31, established from looking at the 55 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Oppenheimer, and HC Wainwright & Co. on February 8, 2024, November 22, 2023, and November 21, 2023. With an average price target of $20 between JP Morgan, Oppenheimer, and HC Wainwright & Co., there's an implied 60.26% upside for Enanta Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Oppenheimer
HC Wainwright & Co.
JMP Securities
RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Enanta Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/08/2024 | ENTA | Buy Now | Enanta Pharma | $12.48 | -11.86% | JP Morgan | Eric Joseph | $12 → $11 | Maintains | Underweight | Get Alert |
| 11/22/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 68.27% | Oppenheimer | Jay Olson | $25 → $21 | Maintains | Perform | Get Alert |
| 11/21/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 124.36% | HC Wainwright & Co. | Ed Arce | $30 → $28 | Maintains | Buy | Get Alert |
| 11/21/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 84.29% | JMP Securities | Roy Buchanan | $42 → $23 | Maintains | Outperform | Get Alert |
| 10/23/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 140.38% | HC Wainwright & Co. | Ed Arce | $48 → $30 | Maintains | Buy | Get Alert |
| 10/02/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 20.19% | RBC Capital | Brian Abrahams | $25 → $15 | Maintains | Sector Perform | Get Alert |
| 09/19/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 284.62% | HC Wainwright & Co. | Ed Arce | → $48 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 100.32% | Oppenheimer | Jay Olson | $30 → $25 | Maintains | Perform | Get Alert |
| 08/08/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 284.62% | HC Wainwright & Co. | Ed Arce | → $48 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 100.32% | RBC Capital | Brian Abrahams | → $25 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/08/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 236.54% | JMP Securities | Roy Buchanan | $65 → $42 | Maintains | Market Outperform | Get Alert |
| 08/08/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 44.23% | Jefferies | Akash Tewari | $49 → $18 | Downgrade | Buy → Hold | Get Alert |
| 05/11/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 140.38% | Oppenheimer | Jay Olson | $50 → $30 | Reiterates | Perform → Perform | Get Alert |
| 05/09/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 164.42% | RBC Capital | Brian Abrahams | $48 → $33 | Maintains | Sector Perform | Get Alert |
| 05/09/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 284.62% | HC Wainwright & Co. | Ed Arce | $68 → $48 | Maintains | Buy | Get Alert |
| 05/09/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 420.83% | JMP Securities | Roy Buchanan | $82 → $65 | Maintains | Outperform | Get Alert |
| 03/22/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 332.69% | RBC Capital | Brian Abrahams | → $54 | Reiterates | → Sector Perform | Get Alert |
| 02/09/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 292.63% | SVB Leerink | Roanna Ruiz | → $49 | Reiterates | → Market Perform | Get Alert |
| 02/08/2023 | ENTA | Buy Now | Enanta Pharma | $12.48 | 597.12% | Piper Sandler | Yasmeen Rahimi | → $87 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Enanta Pharma (ENTA)?
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by JP Morgan on February 8, 2024. The analyst firm set a price target for $11.00 expecting ENTA to fall to within 12 months (a possible -11.86% downside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enanta Pharma (ENTA)?
The latest analyst rating for Enanta Pharma (NASDAQ: ENTA) was provided by JP Morgan, and Enanta Pharma maintained their underweight rating.
When was the last upgrade for Enanta Pharma (ENTA)?
The last upgrade for Enanta Pharmaceuticals Inc happened on July 6, 2022 when Evercore ISI Group raised their price target to $62. Evercore ISI Group previously had an in-line for Enanta Pharmaceuticals Inc.
When was the last downgrade for Enanta Pharma (ENTA)?
The last downgrade for Enanta Pharmaceuticals Inc happened on August 8, 2023 when Jefferies changed their price target from $49 to $18 for Enanta Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Enanta Pharma (ENTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on February 8, 2024 so you should expect the next rating to be made available sometime around February 8, 2025.
Is the Analyst Rating Enanta Pharma (ENTA) correct?
While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a maintained with a price target of $12.00 to $11.00. The current price Enanta Pharma (ENTA) is trading at is $12.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.